ClinicalTrials.gg
CompletedNCT01609907Updated Jun 1, 2012

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

A Phase 1 interventional study of Rosuvastatin+Valsartan (Sequence 1) and Rosuvastatin+Valsartan (Sequence 2) in Hypertension and Hyperlipidemia, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-01.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing rosuvastatin in Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. rosuvastatin · Hypertension.

Enrollment
32nd of 33
30 · median 96
Started
2011
with 1 other
Phase 1
17 of 33
none open now
Registered
3rd of 33
by date
Lead sponsor
3 of 33
Yuhan Corporation

Among the 33 studies testing rosuvastatin in Hypertension, this one is the 32nd largest by enrollment, is one of 2 that started in 2011, is one of 17 in phase 1, and was the 3rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 33 studies testing rosuvastatin in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing rosuvastatin in Hypertension, or all of them as a file.
02

Study summary

The objective of this study is to compare pharmacokinetics after single oral administration of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and valsartan in healthy male volunteers.

03

Conditions studied

  • Hypertension
  • Hyperlipidemia

Keywords

  • Drug interaction
  • YH14700
  • Rosuvastatin
  • Valsartan
  • Yuhan
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers of aged between 20 years to 50 years
  • Have a (BMI) between 19kg/m2 and 27kg/m2 inclusive
  • Eligible subjects with acceptable medical history, physical examination laboratory tests, during screening period
  • Able to follow instruction and can participate in whole procedure of the trial
  • Have signed a written voluntary, prior to the any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the drug
  • Anticipate having the same adult female sexual partner, who have no possibility of being pregnant or breast-feeding and take steps to prevent conception during the study

Exclusion criteria

Exclusion Criteria:

  • Have history of cardiovascular disorder(congestive heart failure, complications of coronary artery stenosis stroke and etc.), respiratory disorder, renal disorder(severe renal failure and etc.), liver disorder(moderate or severe liver failure and etc.) endocrine system disorder(diabetics, impaired glucose tolerance and etc.), digestive system disorder, central nervous system disorder, mental illness or malignant tumor
  • Have history of gastrointestinal disease(Crohn's disease, ulcer and etc.), gastrointestinal surgery(simple appendectomy or herniotomy excluded) that can affect the absorption of the drug
  • Have suffered from a disease within 30 days prior to the first administration
  • Have a known or history of clinically significant hypersensitivity to drugs including the same class drugs with rosuvastatin or valsartan, or other drug(aspirin, antibiotics and etc.)
  • Have genetic myopathy, family history of myopathy, or history of myopathy to drugs
  • Have systolic blood pressure higher than 150mmHg or lower than 90mmHg, or diastolic blood pressure higher than 100mmHg or lower than 60mmHg, or pulse rate more than 100times/min or less than 40times/min
  • Have history of drug abuse or shown positive on drug abuse during drug screening test
  • Participated in any other clinical trials within 90 days prior to the first administration
  • Have used any herbal medicine, prescription drug, or generic medicine within 30 days, 14 days or 7 days prior to the first administration, respectively (provided, however, if other conditions are judged to be eligible by investigators, subjects can participate in the trial)
  • Donated whole blood or blood component within 60 days or 30 days prior to the first administration, respectively, or received transfusion within 30 days prior to the first administration
  • Excessive alcohol drinker(> 140g/week; 1 glass of 12° wine(125mL) = 12.0g, 1 glass of 4° beer(250mL) = 8g, 0.5 bottle of soju(180mL) = 28.8g)
  • Heavy smoker(> 20 cigarettes/day)
  • Excessive caffeine drinker(> 4 cups/day)
  • Shown positive on serum test(, Ab, Ab tests)
  • Subject who is judged to be ineligible by principal investigator or sub-investigator according to various reasons including their abnormal values in clinical laboratory test
  • Continuous increase of liver enzyme level(, ALT) of unknown cause or active liver disorder patients with liver enzyme level increasing more than 3 time of normal upper limit
  • Severe renal disorder patients(with (Cr) \< 10mL/min when calculated with Modification of Diet in Renal Disease method)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Drug: Rosuvastatin+Valsartan (Sequence 1)

  • Experimental
    Sequence 2

    Drug: Rosuvastatin+Valsartan (Sequence 2)

  • Experimental
    Sequence 3

    Drug: Rosuvastatin+Valsartan (Sequence 3)

  • Experimental
    Sequence 4

    Drug: Rosuvastatin+Valsartan (Sequence 4)

  • Experimental
    Sequence 5

    Drug: Rosuvastatin+Valsartan (Sequence 5)

  • Experimental
    Sequence 6

    Drug: Rosuvastatin+Valsartan (Sequence 6)

Interventions

  • DrugRosuvastatin+Valsartan (Sequence 1)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

  • DrugRosuvastatin+Valsartan (Sequence 2)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

  • DrugRosuvastatin+Valsartan (Sequence 3)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

  • DrugRosuvastatin+Valsartan (Sequence 4)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

  • DrugRosuvastatin+Valsartan (Sequence 5)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

  • DrugRosuvastatin+Valsartan (Sequence 6)

    Drug pages: Rosuvastatin · Valsartan

    Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

06

What researchers measure

Primary outcomes

  1. Cmax,ss of valsartan

    Time frame: 18 points up to Day 4

  2. AUCt,ss of valsartan

    Time frame: 18 points up to Day 4

  3. Cmax,ss of rosuvastatin

    Time frame: 18 points up to Day 4

  4. AUCt,ss of rosuvastatin

    Time frame: 18 points up to Day 4

  5. t1/2 of rosuvastatin

    Time frame: 18 points up to Day 4

Secondary outcomes

  1. Tmax,ss of valsartan

    Time frame: 18 points up to Day 4

  2. t1/2 of valsartan

    Time frame: 18 points up to Day 4

  3. Cmin,ss of valsartan

    Time frame: 18 points up to Day 4

  4. Tmax,ss of rosuvastatin

    Time frame: 18 points up to Day 4

  5. Cmin,ss of rosuvastatin

    Time frame: 18 points up to Day 4

  6. t1/2 of rosuvastatin

    Time frame: 18 points up to Day 4

  7. Cmax,ss of N-desmetyl rosuvastatin

    Time frame: 18 points up to Day 4

  8. AUCt,ss of N-desmetyl rosuvastatin

    Time frame: 18 points up to Day 4

07

Study locations

1 site
  • Yuhan Corporation
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2012
First posted
Jun 1, 2012
Start
Nov 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Jun 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01609907
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jun 1, 2012
Start date
Nov 2011
Primary completion
May 2012
Completion
May 2012
Last update
Jun 1, 2012

Study contacts

Woo-Seung Huh, MD, PhD.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Valsartan

Start the discussion